DrugPatentWatch Database Preview

Drugs in Development Information for PBT-1033

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug PBT-1033?

PBT-1033 is an investigational drug.

There have been 7 clinical trials for PBT-1033. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1^st 2019.

The most common disease conditions in clinical trials are Esophageal Neoplasms, Carcinoma, and Endometrial Neoplasms. The leading clinical trial sponsors are xjpfW, NRG Oncology, and National Cancer Institute (NCI).

There are one hundred and eleven US patents protecting this investigational drug and one international patent.

Summary for PBT-1033

US Patents	111
International Patents	1,289
US Patent Applications	417
WIPO Patent Applications	326
Japanese Patent Applications	293
Clinical Trial Progress	Phase 3 (2019-02-01)
Vendors	12

Recent Clinical Trials for PBT-1033

Title	Sponsor	Phase
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT	Jarrow Formulas Inc	Phase 1/Phase 2
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT	University of California, Irvine	Phase 1/Phase 2
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach	University of Maryland, Baltimore	Phase 2

See all PBT-1033 clinical trials

Clinical Trial Summary for PBT-1033

Top disease conditions for PBT-1033

Top clinical trial sponsors for PBT-1033

See all PBT-1033 clinical trials

US Patents for PBT-1033

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
PBT-1033		Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder	Axovant Sciences GmbH (Basel, CH)
PBT-1033		2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides	Pfizer Inc. (New York, NY)
PBT-1033		Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease	Axovant Sciences GmbH (Basel, CH)
PBT-1033		Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors	Pfizer Inc. (New York, NY)
PBT-1033		Combination therapies for the treatment of Alzheimer's disease and related disorders	The General Hospital Corporation (Boston, MA)
PBT-1033		Imidazopyridazine compounds	Pfizer Inc. (New York, NY)
PBT-1033		N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides	Pfizer Inc. (New York, NY)

International Patents for PBT-1033

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
PBT-1033	Argentina	AR104982	2035-06-12
PBT-1033	Australia	AU2016276966	2035-06-12
PBT-1033	Canada	CA2989343	2035-06-12
PBT-1033	China	CN109562085	2035-06-12
PBT-1033	European Patent Office	EP3307260	2035-06-12
PBT-1033	Hong Kong	HK1245660	2035-06-12
PBT-1033	Israel	IL256231	2035-06-12